News Releases

 
News Releases
  Date Title and Summary View
Jun 29, 2016
MOUNTAIN VIEW, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at th...
Jun 16, 2016
-- Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen -- -- Initiation of Phase III development program with CCX168 in ANCA-associated vasculitis planned by the end of 2016 -- MOUNTAIN VIEW, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- C...
Jun 1, 2016
MOUNTAIN VIEW, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (...
May 25, 2016
MOUNTAIN VIEW, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
May 23, 2016
-- Treatment with CCX168 successful in achieving clinical efficacy endpoints while eliminating high-dose oral corticosteroids from current standard-of-care regimen, suggesting a new treatment paradigm for ANCA-Associated Vasculitis -- -- Separately, utilization of CRISPR-Cas9 to create novel models of complement mediated renal diseases such as...
May 12, 2016
MOUNTAIN VIEW, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that preclinical data using a series of orally-available inhibitors of the chemokine rec...
May 11, 2016
MOUNTAIN VIEW, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company will host an R&D Day on Wednesday, May 18, 2016 at 12:00 p.m. Eastern Ti...
May 10, 2016
- Company Announces Exclusive License Agreement with Vifor Pharma to Commercialize Orally Administered Complement 5a Receptor Inhibitor CCX168 in Europe and Certain Other Markets; Agreement Includes $85 Million Upfront, Comprising $60 Million in Cash in Addition to $25 Million Equity Investment - - Patients Complete Treatment Period in AAV Pha...
May 10, 2016
- Vifor Pharma to market drug in selected territories outside the US, ChemoCentryx responsible for worldwide development of CCX168 - - ChemoCentryx to receive USD 85 million comprising USD 60 million in cash and USD 25 million equity investment; Deal also includes regulatory and commercial milestone payments and royalties on net sales to Chemo...
May 5, 2016
MOUNTAIN VIEW, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's first quarter 2016 financial results will be released before market op...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase